A bdominal aortic aneurysm (AAA) is characterized by a progressive local dilation of the vessel and an everincreasing risk of rupture and death. Its incidence increases with age, male sex, and smoking, though other risk factors are associated with AAA, including hypertension, high cholesterol, obesity, lifestyle, and family history of the disease (about 15% of cases).
A bdominal aortic aneurysm (AAA) is characterized by a progressive local dilation of the vessel and an everincreasing risk of rupture and death. Its incidence increases with age, male sex, and smoking, though other risk factors are associated with AAA, including hypertension, high cholesterol, obesity, lifestyle, and family history of the disease (about 15% of cases). 1 AAA pathological hallmarks mainly consist of vessel inflammatory cell infiltration, MMP (metalloproteinase) activation, oxidative stress, and vascular smooth muscle cells depletion, and phenotype switching, which altogether drive extracellular matrix degradation, loss of structural integrity, and progressive weakening of the vessel wall. 2, 3 AAA is largely asymptomatic and no effective medical therapies to stop or decelerate the progression of aneurysmal dilation are currently available. So far, the sole therapeutic approach is vessel repair by either open surgery or endovascular grafting, when the aneurysm features indicate a high likelihood of rupture. The development of effective therapies to halt dilation and prevent vessel rupture requires an in-depth understanding of the mechanisms involved in AAA formation and progression.
Inferences on the pathogenesis of AAA largely rely on data obtained from diverse animal models. 4, 5 Although providing promising findings, these models do not fully recapitulate the pathophysiology of the human disease and integrations with data from investigations on human AAA specimens are, thus, needed.
Molecular profiling of human tissues represents an effective tool to identify disease-specific signatures, which can help to understand the underlying pathobiology and, ultimately, translate the knowledge into clinical applications. 6 In particular, perivascular adipose tissue (PVAT) has a relevant role in vascular function and disease. PVAT is an anatomic PVAT dysfunction is often associated with both atherosclerotic and nonatherosclerotic vascular diseases and is supposed to participate in AAA pathogenesis. 8, 9 Large-scale gene expression profiling has been performed only on full-thickness aortic walls of abdominal aneurysms. 10, 11 Noteworthy, in most cases, the PVAT of the AAA was excised from the samples investigated. Besides, most of the studies compared AAA samples with control aortic tissues obtained from autoptic biopsies, which often yields poor quality RNA and, therefore, may result in altered gene expression profiles. Therefore, the gene expression landscape of the PVAT component of the AAA in humans remains unappreciated so far.
In the present study, we tested the hypothesis that diseasespecific transcriptional profiles characterize the PVAT localized at the site of AAA. To this purpose, we investigated by a genome-wide approach the transcriptome of the adipose stratum surrounding the AAA in comparison with the PVAT of the nondilated proximal neck of the AAA in the same patient. Such a paired-samples approach allowed us to limit confounder effects because of interindividual variability and to increase the overall sensitivity of the analysis. Additionally, we used an in-depth data mining procedure, to tackle the impact of data heterogeneity as produced by high-throughput gene expression techniques 12 overlooked by previous studies. Based on the results obtained, we provide inferences on the functional association between AAA PVAT gene expression signatures and the underlying pathogenic mechanisms.
Materials and Methods
Anonymized data and materials have been made publicly available at the NCBI's GEO repository and can be accessed at https://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE119717.
Study Population
Thirty patients between 60 and 85 years of age with an infrarenal AAA, undergoing elective surgery at Centro Cardiologico Monzino between June 2010 and December 2014, were included in the study. Morphological features of the aneurysms (shape, thrombi content, position, length, and maximum diameter) were acquired from abdominal computed tomography scans performed within 2 months before surgery. The maximum diameter of the aneurysmal lesions ranged from 43.9 to 85.0 mm. Aneurysms with a maximum diameter ≥55.0 (n=7) or <55.0 mm (n=23) were defined as large and small, respectively. Elective repair of both large and small AAA was performed in compliance with the international and national guidelines for the treatment of AAA patients. 13, 14 Exclusion criteria from the study included Marfan syndrome, active or recent (5 years) cancer, recent major surgery (6 months), mycotic aneurysms, or disorders of the immune system, such as autoimmune diseases or vasculitis. Patients' features are reported in the Table and Table I in the online-only Data Supplement. The study was approved by the Ethical Committee of Centro Cardiologico Monzino, and all the participants signed a written informed consent.
Sample Collection
At the time of surgery, samples of diverse adipose tissue (AT) depots were safely obtained sequentially, in the following order: subcutaneous abdominal fat, omental-visceral fat, periaortic fat obtained from the aortic neck, proximal to the aneurismal sac (nondilated PVAT [ND-PVAT]), and periaortic fat surrounding the aneurysmal sac (dilated PVAT [D-PVAT]). The first 3 AT were cleanly obtained by surgical biopsy, whereas the forth was dissected immediately (<3 minutes) from a longitudinal whole-thick wall strip cut out from the anterior excess sac. Care was paid to leave out parts with visible fibrous tissue or vessels. AT samples were immediately snap-frozen in liquid nitrogen and stored at −80°C until processing.
Microarray Gene Expression Analysis
Total RNA was extracted from 50 to 100 mg of frozen AT samples using TRIzol Reagent (Life Technologies, Catalog no.: 15596026) and treated with TURBO DNase (Thermo Fisher Scientific, Catalog no.: AM2238) to eliminate genomic contamination, following manufacturer's instructions. The Infinite M200 PRO multimode microplate reader (Tecan) and the 2100 Bioanalyzer (Agilent Technologies) were used to assess RNA yield/purity and RNA integrity, respectively. Microarray assays were performed through the HumanHT-12 v4 Expression BeadChips (Illumina, Catalog no.: BD-103-0604).
Data Processing
Array data export and quality control were performed with the Genome Studio Software v2011.1 (Illumina). Raw data were imported into the R software v3.4.0 and normalized with the Lumi R/Bioconductor package. 15 Probes with a detection P value <0.01 in at least 30% of the samples were retained. To control systematic heterogeneity in high-throughput data, a data adjustment step was performed through the DaMiRseq R/Bioconductor package. 16 Microarray probes were annotated through the lumiHumanIDMapping and biomaRt R/Bioconductor package.
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Statistical Analysis
Statistical analysis was performed in the R environment v3.4.0. Differential expression analysis was performed through the limma R/Bioconductor package. 19 An additive linear model for a multilevel experiment of paired samples, which includes the tissue type (ie, D-PVAT and ND-PVAT) and the aneurysm size (ie, large and small) factors, was designed as suggested by Smith et al. 20 The implementation of this statistical model, adjusted for the surrogate variables, allowed computing the pair-wise comparisons between (1) D-PVAT versus ND-PVAT on total AAA samples and D-PVAT versus ND-PVAT on the subsets of (2) large and (3) We deemed genes as significantly different at a false discovery rate-adjusted P value <0.05. The robustness of the differential expression analysis results was assessed by exploring the histograms of the P value distribution ( Figure I in the online-only Data Supplement 1), which showed a uniformly flat distribution across the unit interval (null P values) with a peak near zero (P values for alternative hypotheses). 21 The sizepower R/Bioconductor package 22 was used to assess the statistical power of the differential expression analysis for the total paired samples (n=30) and for the small (n=23) and large (n=7) AAA subgroups.
Functional Inferences on Genome-Wide Expression Profiles
The biological functions associated with the differences observed by comparing D-PVAT versus ND-PVAT were inferred by taking advantage of prior biological knowledge on genes grouped by gene ontology (GO) biological processes (BP) and by Reactome pathway database (http://www.reactome.org/) using Gene Set Enrichment Analysis (GSEA, v3.0). 23 To reduce redundancy and visually interpret GSEA data, a network of the most significant GO-BP/Reactome pathway gene sets was drawn through the Enrichment Map software v.2.2.1, 24 implemented as a plug-in in the Cytoscape v.3.5.1 platform. 25 Similarly, a cell-type enrichment analysis to associate specific hematopoietic cell infiltrates with D-PVAT or ND-PVAT was performed by exploiting a custom collection of gene-set cell markers as derived from Newman et al 26 and Simon et al. 27 
Unsupervised Hierarchical Clustering of AT Samples
Unsupervised hierarchical clustering analysis was performed based on the Euclidean metric and the average linkage method, as implemented in the GENE-E software v3.0.215 (http://www.broadinstitute. org/cancer/software/GENE-E/index.html).
Details on RNA isolation, microarray processing protocol, and data analysis parameters are available in the online-only Data Supplement 1.
Results
Gene Expression Dataset
Subsequent to probe-filtering criteria, we identified 18 272 expressed probes. After re-annotation, we obtained a final expression matrix of 14 744 transcripts, which correspond to 11 441 unique genes (annotation details in the online-only Data Supplement 2).
Differential Expression Analysis Between D-PVAT and ND-PVAT Samples
Paired difference tests allowed reducing the effects of confounders and heterogeneity among subjects, thus unveiling specific changes between D-PVAT and ND-PVAT. Overall, we found 335 differentially expressed (DE) transcripts, which stood correction for multiple testing (adjusted P value <0.05) and had an absolute log 2 fold-change (FC, D-PVAT versus ND-PVAT) ≥0.38, ranging from 3.98 to −1.76 ( Figure 1A ). Among them, 193 and 142 transcripts were, respectively, over and underexpressed in D-PVAT compared with ND-PVAT (online-only Data Supplement 2). We then estimated the expected fraction of genes that we correctly declared as DE: the paired-sample size of 30 subjects achieved 99% power to detect gene expression |log 2-FC| ≥0.38. 
Categorical variables are shown as counts (n) and percentage (%); quantitative demographic variables are expressed as median and interquartile range (Q1-Q3). Medications are summarized by drug class. AAA indicates abdominal aortic aneurysm; ACE, angiotensin-converting-enzyme; ARBs, angiotensin II receptor blockers; BMI, body mass index; CeVD, cerebrovascular disease; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HDL-c, high-density lipoprotein cholesterol; and PVD, peripheral vascular disease. Notably, these DE transcripts allowed clearly distinguishing most of the D-PVAT from ND-PVAT samples using Principal Component Analysis ( Figure 1B ). This suggests that AAA PVAT is characterized by a locally restricted expression landscape.
Comparison of D-PVAT Versus ND-PVAT Within Large and Small AAA Subsets
Patients enrolled in this study had aneurysms with different diameters. Because size is the most important morphological surrogate marker of disease severity and progression, 28 we searched for differences within PVATs that were parallel to disease extent, by stratifying samples in large and small AAA according to the maximum aneurysmal diameter (see the above Study population section).
Indeed, we detected a higher number of transcripts (407 versus 100) DE between D-PVAT and ND-PVAT (adjusted P value <0.05) in patients with large AAA with respect to small AAA (online-only Data Supplement 2). Also, the amplitude of differences is higher in the subset of more advanced disease, ranging from (log 2 FC) 4.35 to −2.48 in large AAA and from 3.61 to −0.60 in small AAA ( Figure 2) . In large AAA, 202 transcripts were overexpressed and 205 underexpressed in D-PVAT versus ND-PVAT, whereas in the subset of small AAA 93 transcripts were increased and only 7 decreased in D-PVAT.
The statistical power reached by the large and small AAA subgroups (n=7 and n=23, respectively) was 76% and 99% for |log 2-FC| ≥0.38, respectively. Notably, in the large-AAA subgroup, the vast majority of DE genes had a |log 2-FC| ≥0.40 or ≥0.45 (93% and 75%, respectively): these effect sizes increased the power up to 80% and 95%, respectively, to detect those genes as truly DE.
Finally, to rule out potential confounding effects because of different pharmacological treatments, we performed post hoc comparisons, within the 2 subgroups, between patients treated versus nontreated with 1 or more of the following drugs: Ang II (angiotensin II) receptor blockers, β blockers, and statins (n=5 treated and n=2 nontreated patients, and n=14 and n=9 in large and small AAA, respectively). In fact, the betweengroup differences in the proportion of patients on these 3 drugs were substantial, although not statistically significant (Table) . However, DE analysis did not revealed any statistically significant DE transcript in neither of the 2 subgroups (adjusted P value >0.05; Figure II in the online-only Data Supplement 1).
Functional Inferences From Genome-Wide Expression Analysis in D-PVAT Versus ND-PVAT
Using GSEA, we identified a substantial number of significant pathways/GO-BPs that characterize either D-PVAT or ND-PVAT of AAA samples (online-only Data Supplement 3a). To facilitate data interpretation and visualize the relationships among the most significant pathway/GO-BP gene sets, we drew an enrichment network of GSEA results for paired comparison between D-PVAT versus ND-PVAT (Figure 3) .
The most representative pathways/GO-BP associated with D-PVAT are suggestive for altered immune response and inflammation, which constitute the wider group of highly interconnected gene sets. Among them, we identified pathways/GO-BPs Pink and light blue dots represent significant differentially expressed (DE) transcripts at nominal P value <0.01, whereas red and dark blue dots mark the transcripts that stood adjustment for multiple testing (adjusted P value <0.05), with an absolute log 2 FC ≥0.38. The top 5 up/down DE transcripts with the highest combined rank-score (the product of the log 2 FC×the −log 10 P value) are shown. B, Scatterplot of the first 2 principal components (PC1 and PC2) obtained from the Principal Component Analysis performed on the 335 DE transcripts. PC1 and PC2 explained together 60% variance and allowed discriminating most of the PVAT samples. Red dots and blue triangles represent the D-PVAT and ND-PVAT samples, respectively. Numbers refer to patient's paired samples. ALKAL2 indicates ALK and LTK ligand 2; AP-1, transcription factor subunit-1; CYR61, cysteine-rich angiogenic inducer 61; DES, desmin; DUSP1, dual specificity phosphatase 1; EGR1, early growth response 1; FOS, Fos proto-oncogene; FOSB, FosB proto-oncogene; LDOC1, leucine zipper down-regulated in cancer 1, regulator of NFKB signaling; MYH11, myosin heavy chain 11; and SLN, sarcolipin. related to: (1) innate immunity, including TLR (Toll-like receptor) signaling, Dectin-2 family, type I IFN (interferon)-α and -β signaling, reactive oxygen species, reactive nitrogen species production in phagocytes, complement cascade, and activation and migration of neutrophils, mast cells, macrophages, and dendritic cells; (2) adaptive immunity, including T-and B-cell activation, proliferation and differentiation, T-cell costimulation, antigen processing, presentation and cross-presentation of exogenous antigens; (3) production and signaling regulation of many proinflammatory and anti-inflammatory mediators, for example, IL (interleukins) and chemokines; and (4) signaling pathways such as ERK1/ERK2 (extracellular signal-regulated protein kinases 1 and 2), JAK/STAT (Janus kinase/signal transducers and activators of transcription), JNK (c-Jun N-terminal kinase) NF-kB (nuclear factor kappa-lightchain-enhancer of activated B cells), MAP (mitogen-activated protein)-kinase, NGF (nerve growth factor), CBL (Cbl protooncogene), and phosphatidylinositol 3-kinase cascades.
Remarkably, other pathways/GO-BPs significantly associated with D-PVAT encompassed extracellular matrix degradation and collagen catabolic processes, metabolic processes of macromolecules of the outer membrane cell (ie, sphingolipids, glycosaminoglycans, glycosphingolipids, and proteoglycans), regulated necrosis, DNA damage, and mitosis.
Conversely, the most representative pathways/GO-BPs associated with ND-PVAT (and negatively associated with D-PVAT) were related to smooth muscle contraction, fatty acid oxidation, mitochondrial organization and ATP synthesis, cellular respiration, and mTOR (mechanistic target of rapamycin kinase) signaling.
Functional Inferences Suggestive of AAA Progression
As mentioned above, the maximum AAA diameter is commonly used as a surrogate marker of AAA growth and disease progression. 28 Therefore, we hypothesized that pathways/ GO-BPs uniquely associated with large-AAA D-PVAT were likely related to disease severity and progression. To assess this, we first inferred biological functions associated with D-PVAT versus ND-PVAT separately in large and small AAA by GSEA (online-only Data Supplement 3a). Then, we performed an enrichment network-based comparison to filter out gene sets in common between the 2 subsets and retain those that are solely enriched in large-AAA samples (Figure 4) .
The most relevant pathways/GO-BPs associated with disease severity were mainly related to (1) adaptive immuneresponse mechanisms, such as antigen presentation, T-cell costimulation, leukocyte, and T-cell-mediated cytotoxicity; (2) signaling by proinflammatory cytokines, type I (IFN-α, -β, and -γ); (3) collagen metabolism; (4) metabolic processes of sphingolipids, glycosaminoglycans, ceramides, lipoproteins, and lipopolysaccharides; and (5) regulated necrosis. Conversely, clusters of enriched pathways significantly related with ND-PVAT (ie, negatively associated with D-PVAT) are involved in the regulation of muscle physiological processes.
Cell-Type Enrichment
We further tested whether immune cell types may be differently associated with the D-PVAT or ND-PVAT, by using GSEA with a curated collection of gene markers of 22 subsets of human hematopoietic cells. We found that D-PVAT Figure 1A . ALKAL2 indicates ALK and LTK ligand 2; AP-1, transcription factor subunit; CAP2, cyclase-associated actin cytoskeleton regulatory protein 2; CYR61, cysteine-rich angiogenic inducer 61; DES, desmin; DUSP1, dual specificity phosphatase 1; EGR1, early growth response 1; FOS, Fos proto-oncogene; FOSB, FosB proto-oncogene; HOXC8, homeobox C8; KCNMB1, potassium calcium-activated channel subfamily M regulatory beta subunit 1; LDOC1, leucine zipper down-regulated in cancer 1, regulator of NFKB signaling; MYL9, myosin light chain 9; MYH11, myosin heavy chain 11; and SLN, sarcolipin. ; node gradient color is proportional to the gene-set normalized enrichment score (NES), from lower (light) to higher (dark); node size is proportional to the gene-set size. Edges connect related pathways/GO-BPs. Edge thickness is proportional to the similarity between 2 pathway/GO-BP, for a cutoff=0.15 of the combined Jaccard plus Overlap coefficient. CBL indicates Cbl proto-oncogene; ERK1/ERK2, extracellular signal-regulated protein kinases 1 and 2; FC, fold-change; IFN, interferon; IL, interleukin; JAK/STAT, Janus kinase/signal transducers and activators of transcription; JNK, c-Jun N-terminal kinase; MAP, mitogen-activated protein; mTOR, mechanistic target of rapamycin kinase; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NGF, nerve growth factor; and TRIF, TIR domain-containing adaptor protein including IFN-β.
is significantly associated with most of the hematopoietic cell types (online-only Data Supplement 3b), including neutrophils, eosinophils, CD4+ T-lymphocytes (resting, activated, follicular, and regulatory), CD8+ T-cells, γδ T-cells, B (memory and naïve) lymphocytes, monocytes and macrophages (Mɸ, M1, and M2 subsets), activated NK, resting dendritic cells, and mast cells (resting and activated). Interestingly, this observation is consistent with results from the functional annotation analysis using pathway/GO-BP gene sets, which indicated a strong association of D-PVAT with innate/adaptive immune response and inflammation ( Figure 3) . We also found a few differences between D-PVAT of large compared with small AAA sample subsets. Both resting and activated mast cells were, indeed, significantly associated only with the D-PVAT of small AAA samples, whereas activated dendritic cells were associated with D-PVAT of large-AAA samples.
D-PVAT Showed a Specific Altered Expression Profile
We compared D-PVAT expression profiles with those from other AT depots, to support the hypothesis that local, specific expression patterns in D-PVAT can be directly associated with AAA formation and extent. To this end, we performed an unsupervised hierarchical clustering analysis of D-PVAT versus ND-PVAT, omental-visceral, and subcutaneous abdominal fat samples, based on the expression values of the 335 DE transcripts. We found that 77% of the D-PVAT samples clustered separately from the other 3 AT. We also observed that these transcripts allowed to group separately most of the other AT samples, suggesting that subsets of these 335 transcripts may be related to specific regional differences of adipose depots ( Figure III in the online-only Data Supplement 1).
Notably, a hierarchical clustering analysis restricted to those overexpressed transcripts in D-PVAT that may have a direct pathogenic role in AAA, that is, gene/transcripts involved in the regulation of inflammatory response and lymphocytes activation (Figure 3 ), showed that (1) the fraction of D-PVAT samples that clustered together increased up to 90% and (2) the other AT samples mostly did not form homogeneous clusters ( Figure 5 ). The expression levels of inflammatory and lymphocyte activation transcripts were not substantially different among the ND-PVAT, subcutaneous, and omental-visceral AT (apart from a slight trend towards lower expression in twothirds of the latter AT) and were not useful for discriminating the 3 adipose depots. Consistently, we did not observe any of these inflammatory/immune response transcripts among the top 250 DE transcripts that clearly distinguished ND-PVAT from subcutaneous and omental-visceral AT ( Figure IV in the online-only Data Supplement 1). Overall, these results support our hypothesis that the above-described D-PVAT altered expression patterns are locally restricted and do not systemically involve adipose depots.
Discussion
The pathogenic mechanisms responsible for AAA formation and expansion are largely unknown. Mounting evidence suggests that dysfunctional PVAT may play a role in vascular diseases, including AAA development. 8 To our knowledge, this is the first study showing a relationship between PVAT transcriptome and AAA disease on a genome-wide scale. Our study shows that D-PVAT gene expression patterns are markedly associated with AAA in a locally restricted manner. Two main findings support this conclusion. First, we observed highly consistent, specific, local differences in PVAT gene expression clearly distinguishing the dilated from nondilated portions, which increase in number and magnitude with increasing AAA diameter. These differences did not seem to be substantially influenced by patients' pharmacological regimes. Second, a subset of functionally related genes associated with D-PVAT (ie, inflammatory response genes) allowed discriminating almost all the D-PVAT samples from other AT depots, namely visceral and subcutaneous fat. This finding is coherent with the concept that PVAT inflammation colocalizes with AAA and suggests that the biological changes occurring in PVAT have a functional association with AAA pathogenesis. Indeed, our study, although of an observational nature, is in line with several studies supporting the idea of a putative causative role of PVAT in AAA onset and progression.
Results from experimental studies in animal models indicated a role for localized AT accretion in AAA development. Genetic obesity in ob/ob mice significantly increased the propensity to develop an AAA after Ang II infusion compared with lean controls. This effect was independent of changes in blood pressure and was associated with an increased macrophage accumulation in periaortic AT. 29 High-fat diet fed transgenic mice overexpressing endothelin-1, on an atherosclerosis-prone apolipoprotein E −/− strain, showed accelerated atherosclerosis and AAA formation. Importantly, these phenomena were associated with increased monocyte/macrophage and CD4+ T-cell infiltration and oxidative stress in PVAT, which supports the role of local AT inflammation in AAA development. 30 Our genome-wide molecular profiling allowed further dissecting the putative mechanisms associated with AAA pathogenesis. Functional enrichment analysis revealed a large group of interconnected pathways that pointed to immunerelated functions. We found that both innate and adaptive immune-response genes were strongly overrepresented in D-PVAT compared with ND-PVAT. Interestingly, these enriched immune pathways could be either protective (compensatory responses) or detrimental in the context of AAA. Protective effects could act through the IL-10 and IL-4/IL-13 signaling pathways, which are associated with anti-inflammatory type 2 T-helper lymphocytes and M2 macrophages. These cytokines signaling pathways and cell types could limit the cytotoxic properties of macrophages, increase the differentiation towards the M2 macrophages, and decrease the expression of inflammatory modulators and MMPs. However, a type 2 T-helper immune response has also been invoked to play a part in aneurysm formation and, thus, its role in AAA pathogenesis is not still fully understood. 31, 32 In addition, a pathogenic immune response can result in the activation of different signaling pathways and cell types that lead to the production of inflammatory mediators and a progressive weakening of the aorta. Specifically, our results fit the concept that AAA is an immunologic disease with an underlying autoimmune component that can be responsible, at least in part, for its pathogenesis. 33, 34 In support to this idea, we ascertained the presence of the main hallmarks of an autoimmune response: (1) localized and tissue-restricted damage; (2) mechanisms related to cell death; (3) activation of innate immune response; (4) activation/proliferation of lymphocytes and T-cell costimulatory pathways; and (5) activation of antigen-presenting cells and of antigen processing and presentation machinery.
Extensive mononuclear cell infiltrates, including T-and B-cells and monocytes, but also polymorphonuclear cells, such as neutrophils and mast cells, have been documented in the adventitia layer of the aorta 35 and in the PVAT of AAA. 36 Our enrichment analysis showed that almost all immune cell types were associated with AAA D-PVAT. Interestingly, we found that mast cells were enriched in small but not in large AAA, suggesting that they may play a role in the early phases of AAA development. There is abundant evidence that mast cells are active participants in AAA pathogenesis, 37, 38 orchestrating early recruitment of immune cells, including neutrophils, and acting through the release of mediators that directly prime tissue damage.
Tissue injury induced by immune cells is a well-recognized feature of AAA. Pathways related to cell death were significantly associated with D-PVAT, supporting the notion that prolonged inflammatory responses occurring in AAA results in tissue injury and cell death. Inhibition of the RIPK-1 (receptor-interacting protein kinase 1; a receptor that regulates necroptosis) with Necrostatin-1s was shown to ameliorate disease progression in an elastase-induced AAA mouse model. 39 Notably, we found that the regulation of RIPK-1 mediated regulated necrosis" pathway was significantly associated with large but not with small D-PVAT, suggesting that local cellular necrosis can be effectively related to AAA progression also in humans. Consistently, necrotic adipocytes were found in PVAT of large AAA, promoting the recruitment of immune cells, enhancing inflammation and, in turn, inducing proteolysis of the extracellular matrix. 36 The products of dying cells can activate or enhance innate immune response through binding with the damage-associated molecular pattern receptors, such as the NLR (NODlike receptors) and the TLRs. We found that both NLR and TLR-signaling pathways were strongly enriched in AAA D-PVAT. NLRs may represent a novel signaling pathway for AAA development. Conversely, several works suggested an involvement of TLR signaling in Ang-II-induced aneurysm formation. Mice deficient for the TRIF (TIR domain-containing adaptor protein including IFN-β), which is involved in TLR signaling, showed reduced inflammation, lower infiltration of lymphocytes and macrophages, and decreased level of proteases. 40 The same authors showed an increase of TLR3 and TLR4 in human AAA associated with macrophages, T lymphocytes, endothelial cells, and smooth muscle cells. In leukocytes, depletion of the MYD88 (myeloid differentiation primary response 88) adaptor protein, which modulates TLR signaling, markedly reduced AAA formation. 41 We observed that both TRIF-and MYD88-dependent TLR signaling pathways were enriched in AAA D-PVAT samples, suggesting that TLR-signaling tuning is relevant in AAA pathogenesis. Interestingly, we observed for the first time that the TLR5 and TLR10 cascades were significantly associated only with large AAA, whereas TLR2, 3, 4, and 6 were associated with both large and small AAA, which implicates that different TLRs can play a role in either AAA formation and progression.
Engagement of innate immune receptors by damage-associated molecular pattern induces costimulatory pathways that activate antigen-specific T-cell clones. 42 The T cell costimulation process, which is strictly connected with T-cell activation, was indeed associated with AAA D-PVAT samples. AAA was shown to express early, intermediate and late T-cell activation molecules, and in particular the CD69 marker, which is expressed on T-cells in the early phase of activation and is responsible for the interaction between T-cells and antigen-presenting cell. 43 Accordingly, we found that small AAA expressed the CD69 gene at higher levels in D-PVAT than in ND-PVAT, suggesting that T-cell activation markers are already detectable in the early stage of AAA development. Besides, T-cell proliferation was also enriched in AAA PVAT, which is suggestive of an antigen-driven response typically occurring in autoimmune diseases. Notably, 2 independent studies demonstrated that AAA lesions contain clonally expanded T-cells. 43, 44 Our functional enrichment analysis of AAA PVAT appears in line with these observations. Finally, the finding that also antigenpresenting cells (ie, monocytes/macrophages, dendritic cells, and B-cells) were enriched in AAA D-PVAT supports the possibility that both cellular and humoral adaptive immune response can arise locally. We may speculate that fat-associated lymphoid clusters, a type of tertiary lymphoid organ-like structures within ATs induced by inflammation, 45 represent the tissue-restricted site of interaction between antigen-presenting cell and lymphocytes in AAA PVAT.
Other features of AAA are consistent with the autoimmune response hypothesis. AAA population, including our cohort, has a high percentage of smokers, 46 and it is known that smoke plays a role in autoimmune disease. Smoke can promote oxidative stress, trigger autoantibodies, and unbalance immune-system regulatory mechanisms. 47 Furthermore, cigarette smoke raises the level of sphingolipids such as ceramides. Ceramides, which can promote sterile inflammation 48 and regulate both apoptosis and necrosis, 49 were detected in human samples of AAA PVAT and were correlated with the amount of infiltrating T-cells. 36 Accordingly, sphingolipids and ceramides metabolic processes were enriched in D-PVAT of our large AAA, suggesting that regulation of these molecules may concur to disease progression. Other studies showed that adipocytes derived from PVAT of smokers or stimulated with nicotine presented a proinflammatory phenotype. 50, 51 Taken together, these observations suggest a plausible link between smoking, inflammation, autoimmunity, and AAA pathogenesis. 52 In agreement with previous findings, many BP/pathways that we found significantly enriched in AAA PVAT may participate in AAA pathogenesis. The complement cascade, a process that mediates several immune functions, such as opsonization, chemotaxis, and leukocytes activation, was found activated in human AAA compared with nonaneurysmal controls. 53 The reactive oxygen species, reactive nitrogen species production in phagocytes was shown to contribute to oxidative stress and matrix degradation of the aortic vascular wall. 54, 55 The vascular endothelial growth factor production was shown Figure 6 . Summary of key signaling pathways proposed to be related to abdominal aortic aneurysm (AAA) initiation and progression. Perivascular adipose tissue (PVAT) dysfunction occurs when the physiological functions of PVAT affecting vascular homeostasis are perturbed. AAA-associated risk factors produce alterations in the anti-inflammatory vs proinflammatory balance and can act independently or synergistically on PVAT both as triggers for the initiation of AAA and as persistent stimuli during disease progression. PVAT phenotypic and functional changes switch on inflammatory signals that stimulate immune cell recruitment and activation, with mast cells likely playing a fundamental role in the initial phases. Soluble factors produced by the immune cells start matrix degradation, which in turn feeds, through the permanent activation of the innate and adaptive immune responses, a chronic inflammatory process. The sustained proteolytic imbalance (inducing, eg, collagen destruction) results in tissue injury, cell death, and exposure of autoantigens. This greatly amplifies the autoimmune response by involving different pathways either in AAA initiation or progression. Class-II MHC antigen presentation by antigen-presenting cells (APC), differentiation of type-2 T-helper cells (Th2), and humoral immune response may characterize the initial aneurysmal development. During AAA progression, the adaptive immune response may prevalently turn towards antigen (cross)-presentation via class-I MHC and T-cell mediated cytotoxic response. Other factors, such as aging and genetic components, may contribute to immune response dysfunction and AAA progression. The self-sustaining autoimmune process results in a progressive weakening of the abdominal aorta, which leads to aneurysm expansion and, ultimately, to its rupture. Green and red text indicate mechanisms characterizing AAA early and late phases, respectively. Blue text represents mechanism associated with both initiation and progression of AAA.
to be involved in AAA formation in both Ang II-and CaCl 2 -induced AAA mouse models and its expression was seen to be increased in human AAA samples as well. 56, 57 The collagen metabolic process, which relates to the activity of neutrophil collagenases, would lead to an increase in collagen turnover, a well-known feature of AAA evolution. A progressive imbalance of this process produces an excess matrix destruction and a consequent weakening of the aortic wall. 58 Accordingly, experimental and clinical evidence suggests that collagen integrity, more than elastin, is important to preserve the integrity of the vessel wall and that the strategies to stabilize AAA should focus on the maintenance of the collagen matrix.
2,59
Consistently, we did not observe any enriched process related to elastin metabolism.
AAA is a complex and multifactorial disease. Our approach through functional enrichment and network analysis on genome-wide data allowed picking-up and summarizing an exhaustive picture where multiple mechanisms contribute to defining the intricate phenotype of AAA. To date, most of the published studies on humans displayed results on large aneurysms, which highlighted pathological features related solely to an advanced stage of the disease. In contrast, we might speculate that the differences we highlighted between small and large-AAA PVATs provide insight into the BP that characterize the early versus the late disease stage.
Overall, the model that emerges from our data is consistent with the concept that PVAT plays an active role in the pathogenesis of AAA ( Figure 6 ). In summary, we propose that (1) PVAT dysfunction could induce a proinflammatory state that resolving (anti-inflammatory) mechanisms try to counteract to restore tissue homeostasis. (2) Sustained triggers (eg, noxious high-fat diet or smoke products) dampen the resolution of inflammation and unbalance the benefits of inflammatory response towards a detrimental chronic process. (3) Resulting tissue damage and cell-death produce stimuli that could induce (1) recruitment and activation of innate immune cells, (2) peripheral immune tolerance breaking of T-and/or B-cells, and (3) activation and proliferation of clonal T-cells (ie, autoimmune response). (4) This would amplify inflammation and mechanisms that lead to the progression of AAA, for example, further immune cells recruitment, collagen matrix degradation, oxidative stress, vascular smooth muscle cells phenotype switching/depletion.
To our knowledge, this is also the first study that describes the transcriptional landscape in PVAT of AAA through a genome-wide approach. Our study has many strengths. First, transcriptome analysis is an effective approach to unveil the fingerprint of any changes occurring in response to environmental challenges, different healthy/disease state, or specific genetic/epigenetic programs. Second, our analysis included an in-depth data mining procedure to estimate the effect of unwanted variation, that is, surrogate variables, which commonly affects genome-wide data. Adjusting data for these surrogate variables helped to remove confounding noises while retaining the real effect of the primary variable of interest, ultimately leading to a more accurate data interpretation. Third, we performed the analysis on paired samples by comparing the PVAT surrounding the AAA with the PVAT of the proximal neck in the same patient. This approach effectively reduces the effects of heterogeneity among subjects and increases the overall sensitivity of the analysis. Conversely, most of the published studies compared a few AAA samples with control aorta of autoptic biopsies: the influence of confounding variables in either controls or diseased samples may introduce additional biases that, in turn, can conceal the nature of the pathological signals.
Our work presents also limitations. This is a cross-sectional observational study and the main conclusion relies on inferential analysis. Despite genome-wide approaches and GSEA have been largely demonstrated to be effective in capturing the molecular mechanisms related to specific phenotypes, 6 ,23 a formal demonstration of the autoimmune response hypothesis in the context of AAA PVAT should be the object of further investigation. Furthermore, our cohort is sex-biased because it is exclusively composed of male patients. Although males are prevalent among AAA individuals, we should test our hypothesis in a cohort including both male and female subjects, to generalize the findings of this study. Finally, we analyzed AT transcriptome on whole-tissue RNA extracts, which did not allow estimating the precise contribution of the different cell types. Given PVAT heterogeneity, single-cell RNA-sequencing has the potential benefit to unravel the specific transcriptome at the single-cell level and increase the knowledge on the specific cell type contribution to the disease phenotype.
In conclusion, our work emphasizes the importance of PVAT in the pathogenesis of AAA and suggests that an altered immune response in PVAT is central to the formation and the progression of this elusive disease. Our work also suggests that proper therapeutic approaches should include tuning pathways of the immune response. An immunomodulation strategy should probably be preferred to restore the balance between positive and detrimental immune mechanisms for a truly effective treatment of AAA. 60 
